NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-enabled mobile health services, today announced that it has been selected as winner of the “Compliance ...
BOSTON, May 8, 2025 /PRNewswire/ -- Glytec, the Software-as-a-Service (SaaS) technology leader and pioneer in diabetes and insulin management, today announced that their cloud-based Glucommander ...
NEW YORK, May 8, 2025 /PRNewswire/ -- Capital Rx, Inc., the enterprise health technology company and benefit administrator advancing our nation's electronic healthcare infrastructure, today announced ...
HEKA AI Mattress Named “Best Overall SleepTech Solution” in 2025 MedTech Breakthrough Awards Program
LOS ANGELES, CA, June 9, 2025 (EZ Newswire) -- HEKA, opens new tab, the inventor of the AI mattress and a brand owned by iFutureLab Inc., today announced it has been named “Best Overall SleepTech ...
NEW YORK--(BUSINESS WIRE)--Today, Fruitful, the financial membership helping Americans understand, organize, and optimize their finances, announced that it has been selected as “Best Financial ...
LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CloudBees, a world-leading AI-powered enterprise DevOps solution, today announced that CloudBees Unify Continuous Security has been selected as winner of the ...
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Global educational services provider Kaplan’s All Access License™ has been selected as the winner of the “Test Prep Innovation of the Year” award in the 7th ...
Hosted on MSN
Exclaimer named 'Best Email Signature Management Platform' in 8th annual MarTech Breakthrough Awards programme
The Exclaimer platform helps IT and marketing teams make sure their e-mail signatures are consistent, up to date and compliant. Exclaimer, which positions itself as the global leader in e-mail ...
uniQure announces FDA's Breakthrough Therapy designation for AMT-130, with promising Phase I/II trial safety data and upcoming regulatory updates. uniQure N.V. has announced that its gene therapy ...
- Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder (“MDD”) - The patent, which is expected to provide ...
ObesityWeek 2025, held in Atlanta from November 4-7, showcased unprecedented clinical data that signals a fundamental shift in the obesity treatment landscape. The most striking breakthrough at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback